Epilepsy & behavior : E&B · 2025
Efficacy and safety of long-term combination therapy with lacosamide and oxcarbazepine for pediatric patients with focal epilepsy: real-world clinical experience.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Xueying, Yang Lin, Huang Shaoping, Li Dan, Liu Yu, Guo Yingying, Sun Na, Ye Gaobo, Dang Yonghui
Аннотация
OBJECTIVE: To investigate the clinical efficacy and safety of the combination of lacosamide (LCM) and oxcarbazepine (OXC) in children with focal epilepsy, either as a dual therapy or in combination with other anti-seizure medications.
METHODS: We collected clinical data retrospectively from pediatric epilepsy patients treated with both LCM and OXC for at least 6 months at the Department of Pediatrics, Second Affiliated Hospital of Xi'an Jiaotong University, between January 2021 and July 2023. Efficacy and adverse events were investigated.
RESULTS: Collectively, 69 pediatric patients were included, with ages ranging from 1 to 18 years. The age at onset of epilepsy varied from 15 days to 14.8 years. Disease duration ranged from 1 month to 14 years. All pediatric patients exhibited focal seizures, with the maximum number of concurrent combined medications being six. The maintenance dose of LCM for all pediatric patients was between 3.8 and 10 mg/kg, while that of OXC was between 15 and 40 mg/kg. Over half of the patients showed a greater than 50 % reduction in seizure frequency during long-term follow-up. The most frequently reported adverse reactions included hyponatremia, headache, dizziness, somnolence, and nausea; no patients experienced rash as an adverse reaction.
CONCLUSION: The combination of LCM and OXC has shown promising efficacy and tolerability in pediatric patients with focal epilepsy. This therapeutic combination is a worthwhile option to consider for patients with focal epilepsy, especially those with underlying structural abnormalities.
METHODS: We collected clinical data retrospectively from pediatric epilepsy patients treated with both LCM and OXC for at least 6 months at the Department of Pediatrics, Second Affiliated Hospital of Xi'an Jiaotong University, between January 2021 and July 2023. Efficacy and adverse events were investigated.
RESULTS: Collectively, 69 pediatric patients were included, with ages ranging from 1 to 18 years. The age at onset of epilepsy varied from 15 days to 14.8 years. Disease duration ranged from 1 month to 14 years. All pediatric patients exhibited focal seizures, with the maximum number of concurrent combined medications being six. The maintenance dose of LCM for all pediatric patients was between 3.8 and 10 mg/kg, while that of OXC was between 15 and 40 mg/kg. Over half of the patients showed a greater than 50 % reduction in seizure frequency during long-term follow-up. The most frequently reported adverse reactions included hyponatremia, headache, dizziness, somnolence, and nausea; no patients experienced rash as an adverse reaction.
CONCLUSION: The combination of LCM and OXC has shown promising efficacy and tolerability in pediatric patients with focal epilepsy. This therapeutic combination is a worthwhile option to consider for patients with focal epilepsy, especially those with underlying structural abnormalities.